The prevalence of positive baseline BAT therefore appears low in this population of patients with cancer, but screening for baseline BAT positivity may be useful in future to exclude these infrequent patients from IgE therapy and the associated risk of anaphylaxis. This evidence concerns the gene IGHE and cancer.